Global Information
회사소개 | 문의 | 비교리스트

혈전성 혈소판 감소성 자반증 : 파이프라인 리뷰

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192851
페이지 정보 영문 45 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


혈전성 혈소판 감소성 자반증 : 파이프라인 리뷰 Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 45 Pages

혈전성 혈소판 감소성 자반증은 혈액 난치병으로, 모세혈관 내부에서 혈전이 응고(혈전증)하고 혈소판 수가 감소하는 특징이 있습니다. 주요 증상으로는 피부 및 점막 출혈, 착란, 발열, 두통, 심박수 증가, 호흡 곤란, 실어증, 쇠약, 황달 등을 들 수 있습니다. 주요 치료법에는 비장 적출 수술 및 면역계 억제제(코르티코스테로이드 등) 등이 포함됩니다.

세계 각국에서의 혈전성 혈소판 감소성 자반증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등을 조사하여 전해드립니다.

서론

  • 조사 범위

혈전성 혈소판 감소성 자반증 - 개요

혈전성 혈소판 감소성 자반증 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

혈전성 혈소판 감소성 자반증 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

혈전성 혈소판 감소성 자반증 치료제 개발에 참여하고 있는 기업

약제 개요

혈전성 혈소판 감소성 자반증 - 휴지중인 프로젝트

혈전성 혈소판 감소성 자반증 - 개발이 중지된 제품

혈전성 혈소판 감소성 자반증 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, H1 2020
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2020, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
    • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
    • KM Biologics Co Ltd
    • Lee's Pharmaceutical Holdings Ltd
    • Sanofi
    • Takeda Pharmaceutical Co Ltd
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
    • apadamtase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • caplacizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
  • Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
      • Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise
      • Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura
      • May 25, 2016: Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura
      • Mar 24, 2016: U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q